Cephalon CEO takes medical leave; Chelsea shares boosted by RA trial plans;

 @FierceBiotech: Inspire scuttles eye drug and pencils new deal with Allergan. Article | Follow @FierceBiotech

 @JohnCFierce: So Bloomberg reports that Sanofi is digging in around a $70 Genzyme bid. A pretty clear example of insiders pushing a deal thru leaks. Article | Follow @JohnCFierce

> Cephalon says that its CEO, Frank Baldino, plans to take a medical leave of absence, but declined to specify just what his condition is. During Baldino's absence COO J. Kevin Buchi is taking over temporarily. Cephalon release

> Shares of Chelsea Therapeutics got a boost this morning from the news that the FDA had approved the protocol for a mid-stage trial of its rheumatoid arthritis therapy. Patient screening is scheduled to start next month with data due in mid-2012. Story

> Neuralstem has filed an IND app to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells. Neuralstem release

> Dr. Jürgen Raths has been appointed president and CEO of Iroko Cardio International Sàrl in Geneva. Iroko release

And Finally... A new study concludes that spouses don't become more similar over time, but they do generally start out with a lot in common. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.